RVMD · Revolution Medicines, Inc. · Documents

Aug 7

Earnings call

Q2 2024 earnings call

Aug 7

Current report 8-K Events of Aug 5

Financial results, Director or officer change, or executive pay

Aug 7

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $0 Net loss $133.23M Diluted EPS -$0.81

Jul 15

Current report 8-K

Regulation FD disclosure, Other events

Jun 24

Current report 8-K Events of Jun 20

Shareholder vote results

May 8

Earnings call

Q1 2024 earnings call

May 8

Current report 8-K

Financial results

May 8

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $0 Net loss $116M Diluted EPS -$0.70

May 8

Registration statement S-3ASR

Registration statement

Apr 25

Proxy statement DEF 14A

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Mar 4

Registration statement S-3ASR

Registration statement

Feb 26

Earnings call

Q4 2023 earnings call

Feb 26

Current report 8-K

Financial results

Feb 26

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $11.58M ▼ 67.3% Net loss $436.37M Diluted EPS -$3.86

Jan 9

Current report 8-K

Financial results, Regulation FD disclosure

Dec 26

Current report 8-K/A Events of Nov 8

Current report

Nov 9

Current report 8-K Events of Nov 8

Completed an acquisition or sale of assets, Director or officer change, or executive pay, Shareholder vote results, Regulation FD disclosure

Nov 6

Earnings call

Q3 2023 earnings call

Nov 6

Current report 8-K

Financial results

Nov 6

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $0 Net loss $108.43M Diluted EPS -$0.99

Nov 1

Current report 8-K

Regulation FD disclosure, Other events

Nov 1

Proxy statement DEFA14A

Proxy statement

Oct 23

Current report 8-K Events of Oct 22

Regulation FD disclosure, Other events

Oct 13

Current report 8-K

Other events

Sep 29

Proxy statement DEFM14A

Proxy statement

Sep 27

Registration statement S-4/A

Registration statement

Sep 13

Registration statement S-4

Registration statement

Sep 5

Current report 8-K Events of Aug 31

Director or officer change, or executive pay

Aug 8

Earnings call

Q2 2023 earnings call

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $3.82M ▼ 58.1% Net loss $98.3M Diluted EPS -$0.92

Aug 1

Current report 8-K Events of Jul 31

Entered into a material agreement, Regulation FD disclosure, Other events

Jun 9

Current report 8-K Events of Jun 8

Shareholder vote results

May 8

Earnings call

Q1 2023 earnings call

May 8

Current report 8-K

Financial results

May 8

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $7.01M ▼ 7.4% Net loss $68.1M Diluted EPS -$0.72

Apr 26

Proxy statement DEF 14A

Proxy statement

Apr 26

Annual report to holders ARS

Annual report to holders

Apr 26

Proxy statement DEFA14A

Proxy statement

Mar 7

Current report 8-K Events of Mar 2

Other events

Feb 27

Earnings call

Q4 2022 earnings call

Feb 27

Current report 8-K

Financial results

Feb 27

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $35.38M ▲ 20.4% Net loss $248.71M Diluted EPS -$3.08

Jan 10

Current report 8-K

Financial results, Regulation FD disclosure

Dec 7

Current report 8-K Events of Dec 6

Ended a material agreement

Nov 7

Earnings call

Q3 2022 earnings call

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $3.36M ▲ 204.8% Net loss $73.33M Diluted EPS -$0.87